Literature DB >> 20703241

Analysis of LDLR mRNA in patients with familial hypercholesterolemia revealed a novel mutation in intron 14, which activates a cryptic splice site.

Mari Ann Kulseth1, Knut Erik Berge, Martin Prøven Bogsrud, Trond P Leren.   

Abstract

Familial hypercholesterolemia (FH) is caused by a defective low-density lipoprotein receptor (LDLR), and >1000 mutations in LDLR have been identified. However, in some patients with clinically defined FH, no mutation can be detected within the exons and adjacent intronic segments of the LDLR. We have analyzed RNA extracted from blood samples of patients with clinically defined FH and identified an aberrantly spliced mRNA containing an 81-bp insert from intron 14. The aberrant splicing was caused by a novel intronic mutation, c.2140+86C>G, which activated a cryptic splice site. Although the cryptic splice site does not completely surpass the normal splice site, the mutation was found to cosegregate with high cholesterol levels in a family, which supports the notion that c.2140+86C>G causes FH. The insertion of 81  bp in LDLR mRNA encodes an in-frame insertion of 27 amino acids in the LDLR. However, the insertion was found to hamper LDLR activity by preventing the receptor from leaving the endoplasmic reticulum, probably because of misfolding of the protein. In patients with clinically defined hypercholesterolemia, despite normal results from sequencing of exonic regions of the LDLR gene, characterization of the LDLR mRNA might identify the underlying genetic defect.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20703241     DOI: 10.1038/jhg.2010.87

Source DB:  PubMed          Journal:  J Hum Genet        ISSN: 1434-5161            Impact factor:   3.172


  6 in total

1.  Dysregulation of the Splicing Machinery Is Associated to the Development of Nonalcoholic Fatty Liver Disease.

Authors:  Mercedes Del Río-Moreno; Emilia Alors-Pérez; Sandra González-Rubio; Gustavo Ferrín; Oscar Reyes; Manuel Rodríguez-Perálvarez; Marina E Sánchez-Frías; Rafael Sánchez-Sánchez; Sebastián Ventura; José López-Miranda; Rhonda D Kineman; Manuel de la Mata; Justo P Castaño; Manuel D Gahete; Raúl M Luque
Journal:  J Clin Endocrinol Metab       Date:  2019-08-01       Impact factor: 5.958

2.  Regulation of alternative splicing in obesity and weight loss.

Authors:  Dorota Kaminska; Jussi Pihlajamäki
Journal:  Adipocyte       Date:  2013-04-22       Impact factor: 4.534

3.  RNA-sequencing analysis of HepG2 cells treated with atorvastatin.

Authors:  Camilla Stormo; Marianne K Kringen; Robert Lyle; Ole Kristoffer Olstad; Daniel Sachse; Jens P Berg; Armin P Piehler
Journal:  PLoS One       Date:  2014-08-25       Impact factor: 3.240

4.  The UCL low-density lipoprotein receptor gene variant database: pathogenicity update.

Authors:  Sarah Leigh; Marta Futema; Ros Whittall; Alison Taylor-Beadling; Maggie Williams; Johan T den Dunnen; Steve E Humphries
Journal:  J Med Genet       Date:  2016-11-07       Impact factor: 6.318

5.  Functional changes in mRNA expression and alternative pre-mRNA splicing associated with the effects of nutrition on apoptosis and spermatogenesis in the adult testis.

Authors:  Yongjuan Guan; Guanxiang Liang; Graeme B Martin; Le Luo Guan
Journal:  BMC Genomics       Date:  2017-01-10       Impact factor: 3.969

Review 6.  Alternative RNA Splicing in Fatty Liver Disease.

Authors:  Panyisha Wu; Moya Zhang; Nicholas J G Webster
Journal:  Front Endocrinol (Lausanne)       Date:  2021-02-26       Impact factor: 5.555

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.